October 12-13, 2022 Webconference

The Longwood Healthcare Leaders Fall meeting, centered on Cambridge/Boston via webconference, brings together leading biopharma CEOs, heads of R&D, top academic researchers, and healthcare investors for an off-the-record forum focused on accelerating the translation of discoveries into medicines to help patients.

These meetings are off-the-record and focused on accelerating the translation of discoveries into medicines to help patients; substantial donations enabled by these meetings benefit Life Science Cares, The Boston Foundation, BSO, Harvard Medical School, MIT, and other charities. The Fall 2021 meeting agenda is below.

PAST AGENDA | OCTOBER 4 - 5, 2021

 – all times Eastern Standard –

 

MONDAY, OCTOBER 4, 2021 | AGENDA

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

7:30 – 8:00 | NEWCO TO ESTABLISHED: BUILDING A BIOTECH
PJ Anand, CEO, Alcyone; Philip Astley-Sparke, CEO, Replimune; Jeff Goldberg, CEO, Immunitas; Jim Scibetta, CEO, ImmuneID

8:00 – 8:30 | R&D COLLABORATION
Steve Hitchcock, Head, Research, Takeda; Philip Larsen, Global Head, Research & Early Development, Bayer Pharmaceuticals; Raquel Mura, Head, R&D, North America, Sanofi; Tarek Samad, SVP & Global Head, Research, Lundbeck; Rupert Vessey, President, Research & Early Development, Bristol Myers Squibb

 

8:30 – 8:50 | FIRESIDE CHAT

Marc Casper, CEO, Thermo Fisher Scientific; Stefan Oelrich, CEO, Bayer Pharmaceuticals

Moderator: Christoph Westphal, General Partner, Longwood Fund

 

8:50 – 9:20 | SPOTLIGHT ON INNOVATION
Galit Alter, Co-Director, Center for AIDS Research, Harvard University; Paola Arlotta, Professor and Chair, Stem Cell and Regenerative Biology, Harvard University; David Walt, Professor, Biologically Inspired Engineering, Harvard Medical School; Kai Wucherpfennig, Professor, Neurology, Harvard Medical School, Scientific Co-Founder, Immunitas

 

9:20 – 9:50 | HOW M&A SPURS INNOVATION 
Juergen Eckhardt, Head, Leaps, Bayer; Ivana Magovcevic-Liebisch, CEO, Vigil Neuroscience; Chen Schor, CEO, Adicet Bio

Moderator: Diana Gallagher, Head, External Innovation & New Indications, Biogen

 

9:50 – 10:20 | EXPEDITING RESEARCH FOR TREATMENTS AND CURES
John Connolly, CSO, Parker Institute; Lynn Kramer, Chief Clinical Officer, Eisai; Brad Margus, CEO, Cerevance; Laura Sepp-Lorenzino, CSO, Intellia

Moderator: Ed Kaye, CEO, Stoke Therapeutics

 

10:20 – 10:40 | FIRESIDE CHAT
George Scangos, CEO, Vir Bio; Christophe Weber, CEO, Takeda

Moderator: Christoph Westphal, General Partner, Longwood Fund


10:40 – 11:10 | SOURCING AND IDENTIFYING NOVEL TECHNOLOGY
Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie; Jak Knowles, CEO, Affini-T Therapeutics; Reenie McCarthy, CEO, Stealth BioTherapeutics; Karen Nelson, CSO, Thermo Fisher Scientific

Moderator: Michal Preminger, Regional Head, Johnson & Johnson Innovation, East North America

 

11:10 – 11:40 | PUBLIC-PRIVATE PARTNERSHIPS
PJ Brooks, Program Director, Rare Diseases, NIH; Jonathan Javitt, CEO, NRx; Bill Mezzanotte, EVP, Head R&D & CMO, CSL Behring; Iskra Reic, EVP, Europe & Canada, AstraZeneca; Courtney Silverthorn, AVP, Research Partnerships, Foundation for the NIH

Moderator: Art Krieg, CSO, Checkmate Pharmaceuticals

 

11:40 – 12:00 | REGULATORY KEYNOTE
Peggy Hamburg, former Commissioner, FDA; Janet Woodcock, Acting Commissioner, FDA

Moderator: Christoph Westphal, General Partner, Longwood Fund

 

12:00 – 12:30 | CREATING A WORLD WITHOUT DISEASE
Ivan Cheung, US Chair, Global President, Neurology, Eisai; Mike Devoy, CMO, Bayer; Reed Jobs, Managing Director, Health, Emerson Collective; Sandy Macrae, CEO, Sangamo

Moderator: Bill Hait, Global Head, External Innovation, Johnson & Johnson Innovation

 

12:30 – 1:00 | GLOBAL MARKETS: WORKING ACROSS BORDERS
Hafrun Fridriksdottir, EVP, Global R&D, Teva; Arpa Garay, President, Global Pharmaceuticals, Merck; Ken Keller, CEO, Global Head, Oncology, Daiichi Sankyo Inc.; Paul Perreault, CEO, CSL

Moderator: Philippe Lopes-Fernandes, CBO, Ipsen

 

1:00 – 1:30 | ADVANCING PLATFORM TECHNOLOGIES

Aoife Brennan, CEO, Synlogic; Christina Coughlin, CMO, Rubius Therapeutics; Pearl Huang¸ CEO, Cygnal Therapeutics; Chad May, SVP, R&D, Takeda; Alise Reicin, CEO, Tectonic

Moderator: Annalisa D’Andrea, President & CSO, ImmuneID

 

1:30 – 1:50 | FIRESIDE CHAT
Hal Barron,
CSO & President, R&D, GlaxoSmithKline; Mathai Mammen, Global Head, R&D, Janssen Pharmaceuticals

Moderator: Christoph Westphal, General Partner, Longwood Fund

1:50 – 2:20 | PREPARING FOR THE FUTURE OF R&D
Ray Deshaies, SVP, Global Research, Amgen; Ruxandra Draghia-Akli, Global Head, Global Public Health R&D, Janssen; Anne Heatherington, Head, Data Sciences Institute, Takeda; Frank Nestle, Global Head of Research & CSO, Sanofi

2:20 – 2:50 | DESIGNING THE DEAL
Stacy Coen,
CBO, ImmunoGen; Alban de La Sabliere, SVP, Global Head, Partnering, Sanofi; Nouhad Husseini, SVP, Head, BD, Regeneron; Matthias Muellenbeck, SVP, Head Global BD & Alliance Management, EMD Serono; Patrick Verheyen, Global Head, BD, Janssen

 

2:50 – 3:20 | INNOVATION IN CELL THERAPY
Diana Brainard, CEO, AlloVir; Paul Lammers, CEO, Triumvira; Armon Sharei, CEO, SQZ Biotech; Joanne Smith-Farrell, CEO, Be Biopharma; Pascal Touchon, CEO, Atara

3:20 – 3:40 | FIRESIDE CHAT
John Reed, EVP, Global Head, R&D, Sanofi; Al Sandrock, Head, R&D, Biogen

Moderator: David Steinberg, General Partner, Longwood Fund

3:40 – 4:10 | MAKING A BIG IMPACT WITH LIMITED RESOURCES

Manuel Aivado, CEO, Aileron Therapeutics; Greg Fiore, CEO, Exacis Biotherapeutics; Adelene Perkins, CEO, Infinity Pharmaceuticals; Alice Pomponio, Managing Director, BrightEdge, American Cancer Society; Roger Tung, CEO, Concert Pharmaceuticals

Moderator: Al Beardsley, COO, Galera

4:10 – 4:40 | ACCELERATING DRUG DEVELOPMENT
Jennifer Buell, President & COO, Agenus; Paulo Fontoura, Global Head & SVP, Rare Diseases, Roche; Al Gianchetti, CEO, XyloCor; Sean McClain, CEO, Absci

Moderator: JC Gutierrez-Ramos, CSO, Danaher Corporation

 

4:40 – 5:10 | NOVEL APPROACHES TO DRUG DISCOVERY

Stewart Campbell, CEO, Axial Therapeutics; Fabrice Chouraqui, CEO, Cellarity; Chris Gibson, CEO, Recursion Pharma; Gavin MacBeath, CSO, TScan Therapeutics

Moderator: Bobby Azamian, CEO, Tarsus

5:10 – 5:40 | MAKING SMART INVESTMENTS
Sarah Bhagat, General Partner, Sofinnova; Ansbert Gadicke, Managing Director, MPM Capital; Arjun Goyal, Managing Director, Vida Ventures; Dan Omstead, CEO, Tekla Capital Management

Moderator: Priyanka Rohatgi, Venture Partner, Longwood Fund

 

5:40 – 6:00 | LONGWOOD FUND SUMMARY

Priyanka Rohatgi, Venture Partner, Longwood Fund

 

TUESDAY, OCTOBER 5, 2021

 

7:00 – 7:30 | LONGWOOD FUND INTRODUCTION

 

7:30 – 8:00 | HARNESSING BIOMEDICAL INNOVATION
Shannon Dahl, CSO, Cell Care Therapeutics; Sekar Kathiresan, CEO, Verve Therapeutics; Denitsa Milanova, CEO, Marble Therapeutics; David Southwell, CEO, TScan Therapeutics

Moderator: Chandra Ramanathan, Global Head, Pharma R&D, Open Innovation, Bayer

 

8:00 – 8:30 | MODERATED KEYNOTE

Charlie Baker, Governor, Massachusetts

Moderator: Christoph Westphal, General Partner, Longwood Fund


8:30 – 8:50 | HEALTH SYSTEMS IN A NEW ERA

Laurie Glimcher, CEO, Dana-Farber Cancer Institute; Tom Sequist, Chief Patient Experience & Equity Officer, Mass General Brigham

Moderator: David Steinberg, General Partner, Longwood Fund

 

8:50 – 9:20 | BIG BIOPHARMA R&D
Kathy Fernando,
Head, Operations, WW Research Development & Medical Operations, Pfizer; Larry Hamann, Global Head, Drug Discovery Sciences, Takeda Pharmaceuticals; Jim List, Global Therapeutic Head Cardiovascular, Metabolism, & Retina, Janssen; Christian Rommel, EVP, Head, R&D, Bayer Pharmaceuticals

Moderator: Levi Garraway, EVP, Head of Global Product Development & CMO, Genentech


9:20 – 9:50 | ACCELERATING THE PATH TO PATIENT CARE
Fred Hassan, former Chair & CEO, Pharmacia, Schering-Plough; Kabir Nath, CEO, Otsuka US; Ryan Richardson, Chief Strategy Officer, BioNTech; Melinda Richter, Head, JLabs, Johnson & Johnson Innovation; David Weinreich, EVP, Head, Global Clinical Development, Regeneron

9:50 – 10:20 | DEVELOPING A WORLD-CLASS BOARD
Bill Heiden, Chair, Third Pole Therapeutics; Arlene Morris, Director, Cogent Biosciences; Catherine Sohn, Chair, BioEclipse Therapeutics; Shehnaaz Suliman, Chair, Board Room Ready, Women in Bio

 

10:20 – 10:40 | FIRESIDE CHAT
Bill Anderson, CEO, Roche Pharmaceuticals; David Loew, CEO¸ IPSEN; Paul Perreault, CEO, CSL

Moderator: David Steinberg, General Partner, Longwood Fund


10:40 – 11:10 | SCIENTIFIC INNOVATION: LAUNCHING COMPANIES FROM ACADEMIA
Jessica Grossman, CEO, IgGenix; Richard James, Principal Investigator, Seattle Children's Research Institute; Phil Johnson, CEO, Interius BioTherapeutics; Lloyd Minor, Dean, Stanford School of Medicine

11:10 – 11:40 | CLINICAL TRIAL EFFICIENCY

Derk Arts, CEO, Castor; Steve Potts, CEO, OncoMyx Therapeutics; John Renger, CSO, Cerevel Therapeutics

Moderator: Bill Hinshaw, CEO, Axcella Health

 

11:40 – 12:10 | PERSISTENCE: THE LONG ROAD TO DRUG APPROVAL

Steve Kanes, CMO, Sage Therapeutics; Stuart Peltz, CEO, PTC Bio; Zhen Su, CEO, Marengo Therapeutics

Moderator: Oliver Rosen, CMO, SQZ Biotech

 

12:10 – 12:30 | FIRESIDE CHAT

Vanessa Broadhurst, Company Group Chairman, Global Commercial Strategy, Janssen Pharmaceuticals; Henry Gosebruch, Chief Strategy Officer, AbbVie

Moderator: David Steinberg, General Partner, Longwood Fund

12:30 – 1:00 | INNOVATIVE PARTNERSHIPS

Bram Goorden, COO, SOPHiA GENETICS; Jason Kelly, CEO, Ginkgo Bioworks; Jeremy Levin, CEO, Ovid Therapeutics; Kendra Rose, Head, New Business Development, Bayer

Moderator: Bob Silverman, CBO, Rejuveron

 

1:00 – 1:30 | ACTIONABLE DIVERSITY, EQUITY, AND INCLUSION
Kristen Hege, SVP, Early Clinical Development, Bristol Myers Squibb; Quita Highsmith, Chief Diversity Officer, Genentech; Frank Lee, CEO, Forma Therapeutics

Moderator: Maria Rivas, CMO, EMD Serono

 

1:30 – 2:00 | NOVEL THERAPEUTIC MODALITIES

Liz Buck, CSO, Black Diamond Therapeutics; Brett Monia, CEO, Ionis; Rick Morgan, CSO, Be Biopharma; Anabella Villalobos, SVP, Biotherapeutics & Medicinal Sciences, Biogen; Ottavio Vitolo, CMO, Alcyone

Moderator: Brian McVeigh, CEO, Code Bio

 

2:00 – 2:20 | FIRESIDE CHAT
Mikael Dolsten, CSO & President, Worldwide Research, Development and Medical, Pfizer; Bob Langer, Co-Founder, Moderna/Momenta, NAS; Phil Sharp, Co-Founder, Biogen/Alnylam

Moderator: David Steinberg, General Partner, Longwood Fund

2:20 – 2:50 | EVOLVING BUSINESS STRATEGIES: THE SPIN OUT
Kevin Ali, CEO, Organon; Errik Anderson, CEO, Alloy Therapeutics; Myrtle Potter, CEO, Sumitovant

Moderator: Adam Bruce, Founder & Boardmember, TikoMed

 

2:50 – 3:20 | FROM DATA TO MEDICINE
Christopher Fang, Head of Global Medical Affairs Office, Eli Lilly; Kevin Fitzgerald, CSO, Alnylam; Najat Khan, Chief Data Science Officer, Global Head, R&D Strategy & Operations, Janssen; Michael Mina, Asst. Professor, Epidemiology, Harvard School of Public Health; Lihua Yu, Chief Data Officer, Fog Pharma

Moderator: Paul Schimmel, Professor, Cell & Molecular Biology, Scripps

 

3:20 – 3:40 | FIRESIDE CHAT

Merdad Parsey, EVP & CMO, Gilead; David Reese, EVP, R&D, Amgen; George Yancopoulos, President & CSO, Regeneron

Moderator: Christoph Westphal, General Partner, Longwood Fund

3:40 – 4:10 | INCORPORATING NOVEL DIAGNOSTIC APPROACHES

Alex Aravanis, CTO, Head of Research and Product Development, Illumina; Paul Billings, CMO, Natera; Priti Hegde, CSO, Foundation Medicine; John McAuliffe, Head, CDx Partnering, Roche Diagnostics; Gang Song, Founder and Chairman, Pillar Biosciences

Moderator: Gerald Commissiong, CEO, Todos Medical

 

4:10 – 4:40 | APPROACHES TO REGULATORY HURDLES

Dietmar Berger, CMO, Global Head of Development, Sanofi; Peter Hutt, former General Counsel, FDA; Thomas Lonngren, former Executive Director, EMA; Niels Riedemann, CEO, InflaRx; Raymond Sanchez, CMO, Cerevel Therapeutics

Moderator: Todd Krueger, CEO, AOBiome

 

4:40 – 5:00 | LONGWOOD FUND UPDATE

Aleks Radovic-Moreno, Partner, Longwood Fund

5:00 – 5:30 | EXTERNAL INNOVATION
Henry Gosebruch, Chief Strategy Officer, AbbVie; Mary Lynne Hedley, Senior Fellow, Broad Institute, MIT; Sridaran Natesan, Head, Strategic Initiatives & Science Relations, Sanofi; Chris Viehbacher, Managing Partner, Gurnet Point Capital

Moderator: Nenad Grmusa, Head, Center for External Innovation, Takeda

 

5:30 – 6:00 | PREDICTING SUCCESSFUL INVESTMENTS
Lucio Iannone, VP, Venture Investments, Bayer; Steve Kafka, Managing Partner, Section 32; Judith Li, Partner, Lilly Asia Ventures;

Rene Mora, Portfolio Manager, Monashee Investment Management; Aleks Radovic-Moreno, Partner, Longwood Fund

Moderator: Kyle Lefkoff, General Partner, Boulder Ventures